
Enhertu and Trodelvy Show Promise for First-Line Metastatic Breast Cancer Treatment
Two antibody-drug conjugates, Enhertu (trastuzumab deruxtecan) and Trodelvy (sacituzumab govitecan), delayed disease progression for women receiving initial treatment for locally advanced or metastatic breast cancer, according to a pair of Phase III …